ASTRAZEN
506820Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Please find the enclosed document of the Company in relation to the captioned subject for your reference.
AstraZeneca Pharma India Ltd is the Indian subsidiary of AstraZeneca PLC, a leading global biopharmaceutical company headquartered in the UK. Established in India in 1979, the company focuses primarily on the development, manufacturing, and marketing of prescription medicines in high-need therapy areas such as oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology. It leverages AstraZeneca’s global research and development capabilities to bring innovative therapies to the Indian market, prioritizing unmet medical needs and evidence-based healthcare.
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Please find the enclosed document of the Company in relation to the captioned subject for your reference.
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disclosure Of ESG Rating
Please find the enclosed intimation of the Company in relation to the captioned subject for reference.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find the enclosed Press Release of the Company for your reference.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Outcome Of The Board Meeting Held On Monday, August 10, 2026
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
Please find the enclosed letter of the Company as per the captioned subject for your reference.
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, August 10, 2026
Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Monday, August 10, 2026 inter alia to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2026. We also confirm that the 'Trading Window' remains closed for all Designated Persons, from June 16, 2026 to August 12, 2026 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.
AstraZeneca Pharma India Ltd
About
AstraZeneca Pharma India Ltd is the Indian subsidiary of AstraZeneca PLC, a leading global biopharmaceutical company headquartered in the UK. Established in India in 1979, the company focuses primarily on the development, manufacturing, and marketing of prescription medicines in high-need therapy areas such as oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology. It leverages AstraZeneca’s global research and development capabilities to bring innovative therapies to the Indian market, prioritizing unmet medical needs and evidence-based healthcare.
AstraZeneca Pharma India operates from its headquarters in Bengaluru, with a commercial footprint spanning across major metropolitan regions. Its manufacturing facility in Bengaluru specializes in producing both APIs and finished formulations. The company maintains a robust engagement with the medical fraternity and regulatory authorities, emphasizing ethical marketing, patient-centric initiatives, and sustainability across its operations.
Business Model & Strategy
AstraZeneca Pharma India Ltd generates revenue through the sale and distribution of patented and specialty prescription medicines sourced from its own production facilities and through imports from its global parent. The core business involves direct sales to hospitals, clinics, and pharmacies, with a focus on therapies in oncology, cardiovascular, renal, metabolic, and respiratory segments. It supports its portfolio with scientific engagement, clinical trials, and regular portfolio expansion via new product launches.
Growth strategies include leveraging launches of new patented medicines from AstraZeneca’s global pipeline, targeted expansion of its field force and digital outreach to physicians, and increasing market penetration in Tier II and III geographies. The company invests in localization through manufacturing and clinical development in India, educational initiatives for healthcare professionals, and partnerships with patient advocacy groups to drive adoption.
Management Overview
8 MembersMs.SHILPA DIVEKAR NIRULA
Non-Executive - Independent Director-ChairpersonMs.REVATHY ASHOK
Non-Executive - Independent DirectorMs.MONICA WIDHANI
Non-Executive - Independent DirectorMr.JESUS JAVIER DIAZ-ROPERO ESTESO
Non-Executive - Non Independent DirectorMs.SYLVIA LORENA VARELA RAMON
Non-Executive - Non Independent DirectorMs.HOOI BIEN CHUAH
Non-Executive - Non Independent DirectorMs.BHAVANA AGRAWAL
Executive DirectorMs.Manasa. R
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- 2024: Recognized as 'Top Employer India' by the Top Employers Institute for championing employee conditions
- 2023: Included in the Dow Jones Sustainability Index (Asia Pacific) via AstraZeneca PLC
- 2024: Received CII GreenCo Platinum certification for its Bengaluru manufacturing facility
- 2023: Achieved Great Place to Work certification in India
- 2024: Featured in 'Most Trusted Pharmaceutical Companies' survey by ET Edge
Market Information
Company Timeline
45+ Years of Excellence | 7 Major Milestones
AstraZeneca’s operations established in India
Listed on BSE and NSE
Integration of global AstraZeneca brand after merger of Astra and Zeneca
Inauguration of new manufacturing facility in Bengaluru
Notable oncology launches including Tagrisso (Osimertinib)
Ramp-up of digital initiatives and chronic disease patient programs
Recognition as Top Employer India and CII GreenCo Platinum for Bengaluru plant
The Next Evolution
Contact Information
Registered Office
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Tel: 080-67748000,
Fax: 080-67748857,
Email: comp.secy@astrazeneca.com
Website: astrazeneca.in
Registrars
Integrated Registry Management Services Pvt. Ltd.
Tel: 080 - 23460815 to 818
Email: irg@integratedindia.in
Corporate Actions
8| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹36 per share | 31 Jul 2026 Friday | 31 Jul 2026 Friday | - | - |
Dividend ₹32 per share | 18 Jul 2025 Friday | 18 Jul 2025 Friday | - | - |
Final Dividend ₹24 per share | 05 Jul 2024 Friday | 05 Jul 2024 Friday | - | - |
Dividend ₹16 per share | 14 Jul 2023 Friday | 14 Jul 2023 Friday | - | - |
Final Dividend ₹8 per share | 07 Jul 2022 Thursday | 08 Jul 2022 Friday | - | - |
Interim Dividend ₹2 per share | 18 Aug 2021 Wednesday | 20 Aug 2021 Friday | - | - |
Interim Dividend ₹2 per share | 20 Aug 2020 Thursday | 21 Aug 2020 Friday | - | - |
Interim Dividend ₹1 per share | 20 Aug 2019 Tuesday | 21 Aug 2019 Wednesday | - | - |
₹17,273 Cr.
₹6,927
₹9,850 / 6,886
101.83
₹349.12
19.79
₹67.85
₹2.00
0.52 %
Manage Ratio
FINANCIALS
| Quarterly Results | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | - | - | - | - | - | 165 | 165 | 219 | 196 | 208 | 212 | 227 | 198 | 1,962 | 214 | 203 | 213 | 178 | 201 | 206 | 236 | 236 | 243 | 257 | 293 | 304 | 319 | 315 | 392 | 396 | 416 | 448 | 497 | 538 | 565 | 617 | 585 | 692 | 0 |
| Expenses | - | - | - | - | - | - | - | - | 156 | 150 | 178 | 188 | 174 | 180 | 192 | 185 | 1,698 | 179 | 175 | 176 | 165 | 184 | 190 | 199 | 209 | 199 | 218 | 229 | 232 | 262 | 295 | 338 | 353 | 365 | 373 | 412 | 462 | 487 | 572 | 525 | 641 | 0 |
| Profit | - | - | - | - | - | - | - | - | 6 | 9 | 29 | 10 | 22 | 14 | 27 | 10 | 186 | 26 | 21 | 27 | 10 | 12 | 11 | 28 | 20 | 33 | 29 | 17 | 54 | 52 | 16 | 39 | -11.79 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 | 0 |
| Tax | - | - | - | - | - | - | - | - | 3 | 5 | 12 | -1.35 | 12 | 17 | 8 | 4 | 77 | 9 | 7 | 10 | 3 | 4 | 5 | 9 | 7 | 12 | 10 | 6 | 18 | 21 | 5 | 15 | -3.37 | 13 | 11 | 20 | 19 | 19 | 14 | 13 | 13 | 0 |
| EPS | - | - | - | - | - | - | - | - | 3 | 4 | 12 | 4 | 9 | 6 | 11 | 4 | 7 | 11 | 8 | 11 | 4 | 5 | 5 | 11 | 8 | 13 | 12 | 7 | 22 | 21 | 6 | 16 | -4.72 | 15 | 12 | 23 | 22 | 22 | 13 | 18 | 15 | 0 |
| Ratios | - |
Cash Flow
Standalone Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 | - |
| Equity And Liabilities | - | - | - | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Jun 2016 30 Jun '16 | Sep 2016 30 Sep '16 | Dec 2016 31 Dec '16 | Mar 2017 31 Mar '17 | Jun 2017 30 Jun '17 | Sep 2017 30 Sep '17 | Dec 2017 31 Dec '17 | Mar 2018 31 Mar '18 | Jun 2018 18 Jul '18 | Sep 2018 18 Oct '18 | Dec 2018 11 Jan '19 | Mar 2019 16 Apr '19 | Jun 2019 19 Jul '19 | Sep 2019 22 Oct '19 | Dec 2019 17 Jan '20 | Mar 2020 17 Apr '20 | Jun 2020 21 Jul '20 | Sep 2020 19 Oct '20 | Dec 2020 20 Jan '21 | Mar 2021 20 Apr '21 | Jun 2021 20 Jul '21 | Sep 2021 13 Oct '21 | Dec 2021 20 Jan '22 | Mar 2022 20 Apr '22 | Jun 2022 20 Jul '22 | Sep 2022 18 Oct '22 | Dec 2022 14 Jan '23 | Mar 2023 17 Apr '23 | Jun 2023 19 Jul '23 | Sep 2023 17 Oct '23 | Dec 2023 16 Jan '24 | Mar 2024 15 Apr '24 | Jun 2024 18 Jul '24 | Sep 2024 18 Oct '24 | Dec 2024 18 Jan '25 | Mar 2025 20 Apr '25 | Jun 2025 26 Aug '25 | Sep 2025 19 Oct '25 | Dec 2025 20 Jan '26 | Mar 2026 20 Apr '26 | Jun 2026 20 Jul '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | - | - | - | - | - | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | - |
| Non Institutions | - | - | - | - | - | - | - | - | 18.75% | 19.01% | 19.04% | 18.68% | 18.47% | 18.65% | 19.24% | 20.12% | 20.42% | 20.69% | 21.18% | 21.64% | 21.56% | 21.55% | 21.48% | 21.43% | 21.22% | 21.17% | 20.96% | 20.88% | 20.40% | 19.88% | 19.57% | 18.48% | 17.20% | 17.00% | 16.85% | 17.46% | 17.41% | 17.00% | 16.73% | 16.42% | 16.24% | - |
| FII | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.49% | 2.61% | 2.70% | 2.68% | 2.69% | 2.65% | 2.74% | 2.79% | 2.90% | 2.93% | 2.89% | 3.03% | 2.74% | 2.71% | 2.78% | 2.68% | - |
| DII | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34% | 1.44% | 1.42% | 1.93% | 2.43% | 2.78% | 3.78% | 5.01% | 5.10% | 5.22% | 4.65% | 4.56% | 5.26% | 5.56% | 5.80% | 6.08% | - |
| Total | - | - | - | - | - | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd is the Indian subsidiary of AstraZeneca PLC, a leading global biopharmaceutical company headquartered in the UK. Established in India in 1979, the company focuses primarily on the development, manufacturing, and marketing of prescription medicines in high-need therapy areas such as oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology. It leverages AstraZeneca’s global research and development capabilities to bring innovative therapies to the Indian market, prioritizing unmet medical needs and evidence-based healthcare.
AstraZeneca Pharma India operates from its headquarters in Bengaluru, with a commercial footprint spanning across major metropolitan regions. Its manufacturing facility in Bengaluru specializes in producing both APIs and finished formulations. The company maintains a robust engagement with the medical fraternity and regulatory authorities, emphasizing ethical marketing, patient-centric initiatives, and sustainability across its operations.
AstraZeneca Pharma India Ltd generates revenue through the sale and distribution of patented and specialty prescription medicines sourced from its own production facilities and through imports from its global parent. The core business involves direct sales to hospitals, clinics, and pharmacies, with a focus on therapies in oncology, cardiovascular, renal, metabolic, and respiratory segments. It supports its portfolio with scientific engagement, clinical trials, and regular portfolio expansion via new product launches.
Growth strategies include leveraging launches of new patented medicines from AstraZeneca’s global pipeline, targeted expansion of its field force and digital outreach to physicians, and increasing market penetration in Tier II and III geographies. The company invests in localization through manufacturing and clinical development in India, educational initiatives for healthcare professionals, and partnerships with patient advocacy groups to drive adoption.
2024: Recognized as 'Top Employer India' by the Top Employers Institute for championing employee conditions
2023: Included in the Dow Jones Sustainability Index (Asia Pacific) via AstraZeneca PLC
2024: Received CII GreenCo Platinum certification for its Bengaluru manufacturing facility
2023: Achieved Great Place to Work certification in India
2024: Featured in 'Most Trusted Pharmaceutical Companies' survey by ET Edge
AstraZeneca’s operations established in India
Listed on BSE and NSE
Integration of global AstraZeneca brand after merger of Astra and Zeneca
Inauguration of new manufacturing facility in Bengaluru
Notable oncology launches including Tagrisso (Osimertinib)
Ramp-up of digital initiatives and chronic disease patient programs
Recognition as Top Employer India and CII GreenCo Platinum for Bengaluru plant
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon